TY - JOUR
T1 - Demographic and Clinical Characteristics of Antipsychotic Drug-Treated Older Adults with Bipolar Disorder from the Global Aging & Geriatric Experiments in Bipolar Disorder Database (GAGE–BD) T
AU - Chen, Peijun
AU - Eyler, Lisa T
AU - Gildengers, Ariel
AU - Beunders, Alexandra Jm
AU - Blumberg, Hilary P
AU - Briggs, Farren Bs
AU - Dols, Annemiek
AU - Rej, Soham
AU - Forlenza, Orestes V
AU - Jimenez, Esther
AU - Mulsant, Benoit
AU - Schouws, Sigfried
AU - Orhan, Melis
AU - Sarna, Kaylee
AU - Sutherland, Ashley N
AU - Vieta, Eduard
AU - Tsai, Shangying
AU - Yala, Joy
AU - Villa, Luca M
AU - Sajatovic, Martha
N1 - Funding Information: PC has received publication royalties from UpToDate. LTE received funding for this project from the International Society for Bipolar Disorders (ISBD) Bowden Massey Strategic Research Initiative to her institution as a subcontract and from the National Institutes of Health (NIH) (grant R01MH103318) to her institution for collection of data contributed to the analysis in the manuscript. She also receives direct salary support from the VA Desert-Pacific Mental Illness Research Education and Clinical Center. AG has received funding from the NIH: R01 AG055389 and P30 AG066468, R01 CA149105, and R01 HL131531 for various psychiatry research projects unrelated to the current manuscript. He is also a participant in advisory and monitoring boards for studies NCT02674529 and NCT03128021. HPB received funding for this project from the NIH (grants R01MH070902 and R01MH113230). FBSB has received grants from the National Institute of Nursing Research (NINR), the National Institute of Neurological Disorders and Stroke (NINDS), and the Michael J. Fox Foundation through his institution for various psychiatry research projects unrelated to the current manuscript. HB, Subcontract and from the National Institutes of Health (NIH) 21 (grant R01MH113230). Chen,et al. SR has received a salary award from the Fonds de Recherche Quebec- Funding Information: Abbvie,and holds shares in Aifred Health.Sante,receives grants from Mitacs,is on a steerREPRINTing committee for OVF has received research grants from FAPESP (2019/08507-3, 2014/50873-3), CNPq (465412/2014-9) and Associação Beneficente Alzira Denise Hertzog da Silva (ABADHS), and payments from Biogen for participation in an advisory board and creation of educational information. He receives regularly delivered samples of approved medications and publicity material from several pharmaceutical companies, according to BrazFiliOan Rreg ulations. BM received funding support for this project from the Labatt Family Chair in Depression Biology in Late-Life adults through his institution and has received direct compensation from the Centre for Addiction and Mental Health (CAMH). He has received funding from Brain Canada, the Canadian Institutes of Health Research, the CAMH Foundation, the Patient-Centered Outcomes Research Institute, and Funding Information: EV has received funding from Boehringer-Ingelheim, Janssen, and Funding Information: Research reported in this publication was supported by the International Society for Bipolar Disorders (ISBD) Bowden Massey Strategic Research Initiative in Bipolar Disorder Award and made possible by logistical support from the ISBD. Support was also received from the Clinical and Translational Science Collaborative (CTSC) of Cleveland which is funded by the National Institutes of Health (NIH), National Center for Advancing Translational Science (NCATS),Clinical and Translational Science Award (CTSA) grant, UL1TR002548. The content is solely the responsibility of the authors and do not necessarily Publisher Copyright: © 2022, MedWorks Media LLC. All rights reserved.
PY - 2022/5/31
Y1 - 2022/5/31
N2 - Objectives: Antipsychotic drugs (APS) are widely used to treat patients with bipolar disorder (BD), but there is limited information in older-age bipolar disorder (OABD). This analysis of the Global Aging & Geriatric Experiments in Bipolar Disorder Database (GAGE-BD) investigated characteristics of OABD patients prescribed APS vs. those not prescribed APS.Experimental Design: The observational analysis used baseline, cross-sectional data from 16 international studies for adults aged ≥ 50 years with BD comprising 1,007 individuals with mean age 63.2 years (SD = 9.0), 57.4% women, and mean age of onset 31.6 years (SD = 15.0). The dependent variable was current APS treatment status. The independent variables included demographic and clinical variables, and a random effect for study, that were included in generalized mixed models.Principal Observations: 46.6% of individuals (n = 469) were using APS. The multivariate model results suggest that those treated with APS were younger (p = 0.01), less likely to be employed (p < 0.001), had more psychiatric hospitalizations (p = 0.009) and were less likely to be on lithium (p < 0.001). Of individuals on APS, only 6.6% of those (n = 27) were on first-generation antipsychotics (FGAs) and experienced a greater burden of psychiatric hospitalizations (p = 0.012).Conclusions: APS are widely prescribed in OABD, observed in nearly half of this sample with great variation across sites. Individuals with OABD on APS have more severe illness, more frequent hospitalizations and are more often unemployed vs. those not on APS. Future studies need to examine longitudinal outcomes in OABD prescribed APS to characterize underlying causal relationships.
AB - Objectives: Antipsychotic drugs (APS) are widely used to treat patients with bipolar disorder (BD), but there is limited information in older-age bipolar disorder (OABD). This analysis of the Global Aging & Geriatric Experiments in Bipolar Disorder Database (GAGE-BD) investigated characteristics of OABD patients prescribed APS vs. those not prescribed APS.Experimental Design: The observational analysis used baseline, cross-sectional data from 16 international studies for adults aged ≥ 50 years with BD comprising 1,007 individuals with mean age 63.2 years (SD = 9.0), 57.4% women, and mean age of onset 31.6 years (SD = 15.0). The dependent variable was current APS treatment status. The independent variables included demographic and clinical variables, and a random effect for study, that were included in generalized mixed models.Principal Observations: 46.6% of individuals (n = 469) were using APS. The multivariate model results suggest that those treated with APS were younger (p = 0.01), less likely to be employed (p < 0.001), had more psychiatric hospitalizations (p = 0.009) and were less likely to be on lithium (p < 0.001). Of individuals on APS, only 6.6% of those (n = 27) were on first-generation antipsychotics (FGAs) and experienced a greater burden of psychiatric hospitalizations (p = 0.012).Conclusions: APS are widely prescribed in OABD, observed in nearly half of this sample with great variation across sites. Individuals with OABD on APS have more severe illness, more frequent hospitalizations and are more often unemployed vs. those not on APS. Future studies need to examine longitudinal outcomes in OABD prescribed APS to characterize underlying causal relationships.
KW - Adult
KW - Aged
KW - Aging/psychology
KW - Antipsychotic Agents/therapeutic use
KW - Bipolar Disorder/drug therapy
KW - Cross-Sectional Studies
KW - Demography
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
UR - http://www.scopus.com/inward/record.url?scp=85132261841&partnerID=8YFLogxK
M3 - Article
C2 - 35721813
SN - 2472-2448
VL - 52
SP - 8
EP - 23
JO - Psychopharmacology bulletin
JF - Psychopharmacology bulletin
IS - 2
ER -